The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: a randomized trial
Abstract
INTRODUCTION: Iron deficiency is a common cause of anaemia in non-dialysis chronic kidney disease (ND-CKD). Controversies exist about the optimal route of administration for iron therapy. Liposomal iron, a new generation oral iron with high gastrointestinal absorption and bioavailability and a low incidence of side effects, seems to be a promising new strategy of iron replacement. Therefore, we conducted a study to determine whether liposomal iron, compared with intravenous (IV) iron, improves anaemia in ND-CKD patients. METHODS: In this randomized, open-label trial, 99 patients with CKD (stage 3-5, not on dialysis) and iron deficiency anaemia [haemoglobin (Hb) ≤12 g/dL, ferritin ≤100 ng/mL, transferrin saturation ≤25%] were assigned (2:1) to receive oral liposomal iron (30 mg/day, Group OS) or a total dose of 1000 mg of IV iron gluconate (125 mg infused weekly) (Group IV) for 3 months. The patients were followed-up for the treatment period and 1 month after drug withdrawal. The primary end point was to evaluate the effects of the two treatments on Hb levels; the iron status, compliance and adverse effects were also evaluated. RESULTS: The short-term therapy with IV iron produced a more rapid Hb increase compared with liposomal iron, although the final increase in Hb was similar with either treatment; the difference between the groups was statistically significant at the first month and such difference disappeared at the end of treatment. After iron withdrawal, Hb concentrations remained stable in Group IV, while recovered to baseline in the OS group. The replenishment of iron stores was greater in the IV group. The incidence of adverse event was significantly lower in the oral group (P < 0.001), and the adherence was similar in the two groups. CONCLUSIONS: Our study shows that oral liposomal iron is a safe and efficacious alternative to IV iron gluconate to correct anaemia in ND-CKD patients, although its effects on repletion of iron stores and on stability of Hb after drug discontinuation are lower.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Correction of anemia with epoetin alfa in chronic kidney disease
Singh, A. K., Szczech, L., Tang, K. L., Barnhart, H., Sapp, S., Wolfson, M., & Reddan, D. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa065485 · Cited by 2,762 · cited 1×
“However, on the basis of the results of CREATE [9], CHOIR [10] and TREAT [11] studies, the management of anaemia with ESA aiming at a complete correction or at high values of haemoglobin (Hb) levels has been questioned and the interest in the role of iron treatment has been heightened.”
MethodA trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease
Pfeffer, M. A., Burdmann, E. A., Chen, C.-Y., Cooper, M. E., de Zeeuw, D., Eckardt, K.-U., Feyzi, J. M., Ivanovich, P., Kewalramani, R., Levey, A. S., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0907845 · Cited by 2,096
Cited by
Lopez, A., Cacoub, P., Macdougall, I. C., & Peyrin-Biroulet, L. (2016) · The Lancet · doi:10.1016/s0140-6736(15)60865-0 · Cited by 1,492
Camaschella, C. (2019) · Blood · doi:10.1182/blood-2018-05-815944 · Cited by 702
Iron Absorption: Factors, Limitations, and Improvement Methods
Piskin, E., Cianciosi, D., Gulec, S., Tomas, M., & Capanoglu, E. (2022) · ACS Omega · doi:10.1021/acsomega.2c01833 · Cited by 543
Lenti, M. V., Rugge, M., Lahner, E., Miceli, E., Toh, B.-H., Genta, R. M., De Block, C., Hershko, C., & Di Sabatino, A. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0187-8 · Cited by 350
Iron Deficiency in Chronic Kidney Disease: Updates on Pathophysiology, Diagnosis, and Treatment
Batchelor, E. K., Kapitsinou, P., Pergola, P. E., Kovesdy, C. P., & Jalal, D. I. (2020) · Journal of the American Society of Nephrology · doi:10.1681/asn.2019020213 · Cited by 334
Metadata
- Authors
- Pisani, A., Riccio, E., Sabbatini, M., Andreucci, M., Del Rio, A., & Visciano, B.
- Venue
- Nephrology Dialysis Transplantation
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-11-13
- Volume
- 30
- Issue
- 4
- Pages
- 645-652
- ISSN
- 0931-0509 (ISSN-L)
- 1460-2385
- OpenAlex
- W2155330191
- Cited by
- 162
- References
- 2
- FWCI
- 5.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: a randomized trial. https://app.cochat.ai/papers/10.1093/ndt/gfu357
- The paper
- Pisani, A., Riccio, E., Sabbatini, M., Andreucci, M., Del Rio, A., & Visciano, B. (2015). Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: a randomized trial. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfu357
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.